NCT Number: NCT02177305
Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers
Safety and tolerability after ocular administration
Looking for future studies?
Notify MeKey information
Conditions
Age range
21 year–50 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy males
- Age range from 21 to 50 years
- Within ± 20% of normal weight (Broca-Index)
- Written informed consent given
Exclusion criteria
- Results of the medical examinations or laboratory tests are judged by the clinical investigator to differ significantly from normal clinical values
- Volunteers with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Volunteers with disease of the central nervous system (such as epilepsy) or with psychiatric disorders
- Volunteers with known history of orthostatic hypotension, fainting spells or blackouts
- Volunteers with chronic or relevant acute infections
- Volunteers with history of allergy/ hypersensitivity (including drug allergy)
- Volunteers with known eye diseases (incl. glaucoma), with hyperopia (> 3 diopters) or with contact lenses
- Volunteers with intraocular pressure > 22 mmHg
- Volunteers with predisposition to narrow-angle glaucoma
- Volunteers with disturbed micturition
- Volunteers who have taken a drug with a long half-life (≥ 24 hours) within ten half-lives of the respective drug before enrolment in the study
- Volunteers who received any other drugs which might influence the results of the trial during the week previous the start of the study
- Volunteers who have participated in another study with an investigational drug within the last two months preceding this study
- Volunteers who smoke (> 10 cigarettes or 3 cigars or 3 pipes/day)
- Volunteers who are not able to refrain from smoking on study day
- Volunteers who drink more than 40 g of alcohol per day
- Volunteers who are dependent on drugs
- Volunteers who have donated blood (≥ 100 ml) within the last four weeks
- Volunteers who participated in excessive physical activities (e.g. competitive sports) within the last week before the study
Treatment and study plan
0.04 mcg tiotropium solution
Drug0.08 mcg tiotropium solution
Drug0.16 mcg tiotropium solution
Drug0.28 mcg tiotropium solution
Drug0.40 mcg tiotropium solution
DrugPlacebo solution
DrugPrimary outcomes
-
Change in pupil diameter
Time frame: baseline, after 24 hours
-
Change in pupillary reflex
Time frame: baseline, after 24 hours
-
Change in intraocular pressure
Time frame: baseline, after 24 hours
-
Change in accommodation
Time frame: baseline, after 24 hours
Secondary outcomes
-
Change from baseline in blood pressure
Time frame: on Day 1 before and 24 hours after treatment and within 8 days after treatment day
-
Change from baseline in pulse rate
Time frame: on Day 1 before and 24 hours after treatment and within 8 days after treatment day
-
Change in 12-lead ECG
Time frame: on Day 1 before and 24 hours after treatment and within 8 days after treatment day
-
Changes from baseline in standard laboratory examinations
Time frame: Baseline and within 8 days after treatment day
-
Occurrence of Adverse Events
Time frame: until 8 days after treatment day
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
A Single Increasing Dose Tolerance Study After Ocular Administration of Tiotropium (Single Doses: 0.02 - 0.4 mcg) in Healthy Male Volunteers (Randomised, Placebo-controlled, Double-blind, Parallel Groups).
Important dates
- Study start
- 1998
- Primary completion
- 1998
- First posted
- Jun 27, 2014
- Registry last updated
- Jun 27, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
NCT06702423
Healthy
London, United Kingdom
View Trial DetailsValidation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
NCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNormative Value for Navicular Drop Test in Older Adults
NCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details